Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
| Autor: | Luigi Boni, Federico Perna, Tania Contardo, Sergio Gentilli, Elena Traverso, Igor Monsellato, Riccardo Rosati, Davide Cavaliere, Maura Rossi, Giorgio Ercolani, Valter Torri, Ludovica Baldari, Filippo Alongi, Paolo Baroffio, Leonardo Solaini, C Ceccarelli, Elisa Cassinotti, Fabio Pulighe, Piero Buccianti, Emilio Morpurgo, Andrea Coratti, Benedetta Menegatti, Enzo Mammano, Graziano Pernazza, Sara Orecchia, Riccardo Balestri, Elisa Bertocchi, C. De Nisco, Roberto Delpini, Ugo Elmore, Stefania Gori, Roberto Perinotti, Fabio Priora, Paola Franzone, Vittorio Fusco, Gianmauro Numico, Giacomo Ruffo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Neoadjuvant treatment Time Factors Colorectal cancer Adenocarcinoma lcsh:RC254-282 Disease-Free Survival Young Adult Study Protocol Minimally invasive surgery Genetics Humans Minimally Invasive Surgical Procedures Medicine Prospective Studies Rectal cancer Aged Group trial Rectal Neoplasms business.industry Correction Cancer Robotic surgery Chemoradiotherapy Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis medicine.disease TaTME Neoadjuvant Therapy Surgery Radiation therapy Oncology Invasive surgery Laparoscopy Timing to surgery business Neoadjuvant chemoradiotherapy |
| Zdroj: | BMC Cancer BMC Cancer, Vol 20, Iss 1, Pp 1-1 (2020) |
| ISSN: | 1471-2407 |
| Popis: | Background The optimal timing of surgery in relation to chemoradiation is still controversial. Retrospective analysis has demonstrated in the recent decades that the regression of adenocarcinoma can be slow and not complete until after several months. More recently, increasing pathologic Complete Response rates have been demonstrated to be correlated with longer time interval. The purpose of the trial is to demonstrate if delayed timing of surgery after neoadjuvant chemoradiotherapy actually affects pathologic Complete Response and reflects on disease-free survival and overall survival rather than standard timing. Methods The trial is a multicenter, prospective, randomized controlled, unblinded, parallel-group trial comparing standard and delayed surgery after neoadjuvant chemoradiotherapy for the curative treatment of rectal cancer. Three-hundred and forty patients will be randomized on an equal basis to either robotic-assisted/standard laparoscopic rectal cancer surgery after 8 weeks or robotic-assisted/standard laparoscopic rectal cancer surgery after 12 weeks. Discussion To date, it is well-know that pathologic Complete Response is associated with excellent prognosis and an overall survival of 90%. In the Lyon trial the rate of pCR or near pathologic Complete Response increased from 10.3 to 26% and in retrospective studies the increase rate was about 23–30%. These results may be explained on the relationship between radiation therapy and tumor regression: DNA damage occurs during irradiation, but cellular lysis occurs within the next weeks. Study results, whether confirmed that performing surgery after 12 weeks from neoadjuvant treatment is advantageous from a technical and oncological point of view, may change the current pathway of the treatment in those patient suffering from rectal cancer. Trial registration ClinicalTrials.gov NCT3465982. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |